Do you want to read an article? Please log in or register.
Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort study
Inflamm Bowel Dis
Ünal NG, Bakkaloğlu OK, Kav T, Eşkazan T, Kani HT, Akpınar A, Akıncıoğlu P, Dağcı G, Şendur İ, Büyüktorun İ, Barutçu S, Kılıç G, Bengi G, Çavuş B, Oruç N, Alahdab YÖ, Atuğ Ö, Dinçer D, Karakan T, Hatemi Aİ, Erzin YZ, Tezel A, Törüner M, Akyüz F, Çelik AF
doi: 10.1093/ibd/izag126
Inflammatory Bowel Disease
Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis
Clin Gastroenterol Hepatol
Privitera G, Bezzio C, Figlioli G, D'Amico F, Mendes J, Varca S, Zingone F, Lago IR, Onali S, Caprioli FA, Chaparro M, Acosta MB, Karmiris K, Degabli NT, Dar L, Pastorelli L, Gutiérrez A, Orlando A, Zabana Y, Saibeni S, Piovani D, Savarino EV, Pugliese D, Magro F, Danese S, Armuzzi A, PODIUM Study Group, Bonovas S, Fanizzi F, Ferraz P, Scaldaferri F, Barberio B, Moraleja I, Favale A, Noviello D, Gisbert JP, Porto-Silva M, Psistakis A, Yanai H, Kopylov U, Di Pietro M, Madero-Velázquez L, Macaluso FS, Orlando R, Gabbiadini R, Buono AD, Loy L, Migliorisi G, Zoratti C
doi: 10.1016/j.cgh.2026.01.017
Inflammatory Bowel Disease
Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study
Adv Ther
Tursi A, Pasta A, Elisei W, Barberio B, Mocci G, Savarino EV, de Barba C, Maconi G, Cataletti G, Scaldaferri F, Napolitano D, Costa F, Ceccarelli L, Marzo M, Monterubbianesi R, di Fonzo M, Lombardi G, Patturelli M, Ribaldone DG, Bertani L, Rodino' S, Sebkova L, Bodini G, Pranzo G, Serio M, Scarcelli A, Luppino I, Ferronato A, Spagnuolo R, Luzza F, Morano D, Gravina AG, Pellegrino R, Vespere G, Sedda S, Allegretta L, Fanigliulo L, Grossi L, Cortellini F, Forti G, Neve V, Piergallini S, Scarozza P, Bevevino G, Iacopini F, Capone P, Gaiani F, Kayali S, Mucherino C, D'antonio E, D'ascoli B, Colucci R, Bachetti F, Giorgetti GM, Clemente V, Pagnini C, Cuomo A, Donnarumma L, Onidi FM, Satta PU, Picchio M, Papa A, Italian Network for Inflammatory Bowel Diseases (IN-IBD)
doi: 10.1007/s12325-026-03622-3
Helicobacter Pylori
Efficacy and Safety of Levofloxacin- Versus Moxifloxacin-Based Nitazoxanide Quadruple Therapy as Second-Line Treatment for Helicobacter pylori in Egypt: A Randomized Multicenter Trial
Helicobacter
El-Azab G, Abdel Salam S, Moustafa E, Abuoelhassan A, Shamseya A, Ellakany A, Abdelaal U, Assem M, Khalil F, Mahmoud A, Elsabaawy M, Hussein B, Ezz-Eldin M, Hassany S, Zaghloul N, Magdy M
doi: 10.1111/hel.70104
Inflammatory Bowel Disease
Effectiveness and safety of mirikizumab in patients with moderate-to-severe ulcerative colitis: the miri real multicenter study
J Crohns Colitis
D'Amico F, Fanizzi F, Dal Buono A, Gabbiadini R, Nardone OM, Zilli A, Allocca M, Lauriola GM, Jairath V, Peyrin-Biroulet L, Fiorino G, Castiglione F, Massimino L, Mastronardi M, Armuzzi A, Danese S
doi: 10.1093/ecco-jcc/jjag062
Inflammatory Bowel Disease
Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study
Lancet Gastroenterol Hepatol
Visser E, Reijntjes MA, Heuthorst L, Stellingwerf ME, West R, van Dongen K, Crolla RMPH, van Dieren S, van der Bilt JDW, Bemelman WA, D'Haens GR, Buskens CJ, COSTA Study Group
doi: 10.1016/S2468-1253(25)00291-2
RECOMMENDED
Inflammatory Bowel Disease
Efficacy of 5-Aminosalicylic Acid Continuation versus Discontinuation in Patients with Ulcerative Colitis Escalated to Advanced Therapy: A Systematic Review and Meta-Analysis of Adjusted Effect Estimates
★ 1
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis
Sul HH, Gewehr DM, Kang H, Junior OR, Ungaro RC, Bernstein CN
doi: 10.1093/ecco-jcc/jjaf202
Inflammatory Bowel Disease
Efficacy and safety of ulcerative colitis therapies do not differ by age: A post hoc analysis of randomized controlled trials
Inflamm Bowel Dis
Wong ECL, Marshall JK, Ma C, Jairath V, Reinisch W, Narula N
doi: 10.1093/ibd/izag054
Inflammatory Bowel Disease
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial
Lancet Gastroenterol Hepatol
Long M, Allegretti JR, Danese S, Germinaro M, Baker T, Alvarez Y, Kavalam M, Han C, Jörgens S, Jiang L, Zhang H, Hisamatsu T, Rubin DT, Peyrin-Biroulet L, ASTRO Study Group
doi: 10.1016/S2468-1253(25)00322-X